Strategies for Effective Pain Management
March 19, 2020 | 11:00 AM - 2:45 PM ET
The nation is facing competing public health issues: the need to treat a large number of Americans with acute and chronic pain versus the crisis of prescription opioid abuse. Pri-Med’s Strategies for Effective Pain Management curriculum focuses on improving practitioners’ ability to recognize, diagnose, and classify pain; educating clinicians on the full spectrum of pain management options, including non-opioid pharmacologic interventions; and providing risk reduction strategies through integration of opioids into individualized pain management plans. Clinicians will learn to recognize signs and symptoms of opioid dependence and abuse to manage patients’ pain and medication use optimally.
Professor of Neurology
Albany Medical College
Director, Comprehensive Pain Center
Albany Medical Center
Professor of Anesthesiology and Medicine
The Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
Chief, Pain Medicine and Professor of Oncology
Roswell Park Cancer Institute
The following relevant financial relationships have been disclosed by faculty:
Charles E. Argoff, MD
Advisory Board for Grünenthal; Lilly USA, LLC; Scilex Pharmaceuticals, Inc.; Teva Pharmaceuticals; US WorldMeds; and Vertex Pharmaceuticals. Consultant for Celexo; Nevro; and Pfizer. Contracted Research for Lilly USA, LLC and Teva Pharmaceuticals. Ownership Interest in Pfizer (e.g. stock, patent holder). Speaker’s Bureau for Allergan; Amgen; Biohaven Pharmaceutical; Lilly USA, LLC; Novartis; Teva Pharmaceuticals; and Theranica.
Oscar A de Leon-Casasola, MD
Advisory Board for Adapt Pharma Inc.; Esteve Pharma; Medtronic; and Stimgenics
Katherine E. Galluzzi, DO, CMD, FACOFP
No financial relationships disclosed.
Non-faculty contributors involved in the planning, development, editing, and review of the content have disclosed no relevant financial relationships.
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Pri-Med Institute designates this live activity for a maximum of 3.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pri-Med Institute is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider Number 040308.
This program has been approved for 3.50 contact hours of continuing education, including 0.88 hour of pharmacology.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 3.50 Medical Knowledge & Patient Safety MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Information collected during this activity will be shared, only in aggregate, with the commercial supporter of the activity. This may include general participant demographics, polling questions responses, and evaluation responses.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). For guidance on how clinicians can attest to participation in a MIPS Improvement Activity, visit https://qpp.cms.gov/mips/improvement-activities
Opioid Analgesic REMS Program Companies
Miller Medical Communications, LLC
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
pmiCME Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. pmiCME, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. pmiCME is the accredited provider for this activity.
Disclosures and Conflict of Interest
pmiCME requires all individuals in a position to influence educational content for pmiCME-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. pmiCME assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by pmiCME or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email email@example.com or call (877) 477-4633.